BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 17950913)

  • 21. The history and future prospective of haplo-identical stem cell transplantation.
    Handgretinger R; Lang P
    Cytotherapy; 2008; 10(5):443-51. PubMed ID: 18615344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of fetal-maternal tolerance in hematopoietic stem cell transplantation.
    Teshima T; Matsuoka K; Ichinohe T
    Arch Immunol Ther Exp (Warsz); 2006; 54(3):165-72. PubMed ID: 16652218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance.
    Obama K; Utsunomiya A; Takatsuka Y; Takemoto Y
    Bone Marrow Transplant; 2004 Nov; 34(10):897-9. PubMed ID: 15361902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation.
    Chen XH; Gao L; Zhang X; Gao L; Zhang C; Kong PY; Liu H; Peng XG; Sun AH; Qi DG; Gong Y; Wang QY
    Blood Cells Mol Dis; 2009; 43(1):98-104. PubMed ID: 19356956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular immune reconstitution after haploidentical transplantation in children.
    Handgretinger R; Chen X; Pfeiffer M; Schumm M; Mueller I; Feuchtinger T; Hale G; Lang P
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):59-65. PubMed ID: 18162222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.
    Ruggeri L; Mancusi A; Burchielli E; Perruccio K; Aversa F; Martelli MF; Velardi A
    Semin Cancer Biol; 2006 Oct; 16(5):404-11. PubMed ID: 16916611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of transplantation tolerance in haploidenical transplantation under reduced intensity conditioning: the role of ex-vivo generated donor CD8+ T cells with central memory phenotype.
    Ophir E; Eidelstein Y; Bachar-Lustig E; Hagin D; Or-Geva N; Lask A; Reisner Y
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):393-401. PubMed ID: 21925092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children.
    Liu D; Huang X; Liu K; Xu L; Chen H; Han W; Chen Y; Zhang X; Jiang Q
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):469-77. PubMed ID: 18342790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation.
    Grosso D; Flomenberg N
    Semin Oncol; 2012 Dec; 39(6):694-706. PubMed ID: 23206846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity.
    Aversa F; Martelli MF; Velardi A
    Semin Oncol; 2012 Dec; 39(6):643-52. PubMed ID: 23206841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation.
    Meyer-Monard S; Passweg J; Siegler U; Kalberer C; Koehl U; Rovó A; Halter J; Stern M; Heim D; Alois Gratwohl JR; Tichelli A
    Transfusion; 2009 Feb; 49(2):362-71. PubMed ID: 19389215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia.
    Xu LP; Luo XH; Chang YJ; Liu DH; Liu KY; Chen YH; Huang XJ
    Ann Hematol; 2009 Oct; 88(10):1015-24. PubMed ID: 19319533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome.
    Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):734-44. PubMed ID: 17531784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.
    Kanda Y; Oshima K; Kako S; Fukuda T; Uchida N; Miyamura K; Kondo Y; Nakao S; Nagafuji K; Miyamoto T; Kurokawa M; Okoshi Y; Chiba S; Ohashi Y; Takaue Y; Taniguchi S
    Am J Hematol; 2013 Apr; 88(4):294-300. PubMed ID: 23450467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haploidentical stem cell transplantation in leukemia.
    Aversa F; Velardi A; Tabilio A; Reisner Y; Martelli MF
    Blood Rev; 2001 Sep; 15(3):111-9. PubMed ID: 11735159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference.
    Locatelli F; Pende D; Maccario R; Mingari MC; Moretta A; Moretta L
    Clin Immunol; 2009 Nov; 133(2):171-8. PubMed ID: 19481979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.